Results 81 to 90 of about 47,532 (242)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Changing behaviour [PDF]

, 2006
Individual change in behaviour has the potential to decrease the burden of chronic disease due to smoking, diet and low physical activity. Smoking quit rates can be increased by simple advice from a physician or trained counsellor, overall and in ...
Hillsdon, Melvyn, Summerbell, Carolyn, Thorogood, Margaret   +2 more
core   +1 more source

Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial

PLoS ONE, 2017
Objective To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington’s disease (HD). Methods In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals with HD and clinical signs of apathy ...
H. Gelderblom, T. Wüstenberg, T. McLean, Lisanne Mütze, W. Fischer, C. Saft, R. Hoffmann, S. Süssmuth, P. Schlattmann, E. van Duijn, B. Landwehrmeyer, J. Priller   +11 more
semanticscholar   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence. [PDF]

, 2009
Despite the worldwide extent of methamphetamine dependence, no medication has been shown to effectively treat afflicted individuals. One relatively unexplored approach is modulation of cholinergic system function.
Clement, Clayton, De La Garza, Richard, London, Edythe D, Miotto, Karen, Newton, Thomas F, Sevak, Rajkumar J, Shoptaw, Steven, Swanson, Aimee-Noelle, Zorick, Todd   +8 more
core  

Gender-related issues in the pharmacology of new anti-obesity drugs [PDF]

, 2019
Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease.
Barrea, Luigi, Cataldi, Mauro, Colao, Annamaria, Guida, Bruna, Muscogiuri, Giovanna, Savastano, Silvia, Taglialatela, Maurizio   +6 more
core   +1 more source

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Bupropion as Treatment for Methadone-Emergent Sexual Dysfunction in Men

American Journal of Men's Health, 2018
Methadone is largely recognized as an effective treatment for opiate-dependent patients; however, it causes reduced brain dopaminergic action resulting in significant sexual dysfunction.
A. Yee, H. S. Loh, T. Ong, C. G. Ng, A. Sulaiman   +4 more
semanticscholar   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source

Nonresponse to High-Dose Bupropion for Depression in a Patient Carrying CYP2B6 *6 and CYP2C19 *17 variants: a case report [PDF]

, 2020
Céline K. Stäuble, Markus L. Lampert, Thorsten Mikoteit, Martin Hatzinger, Kurt E. Hersberger, Henriette E. Meyer zu Schwabedissen   +5 more
openalex   +1 more source

Smoking cessation in severe mental ill health : what works? an updated systematic review and meta-analysis [PDF]

, 2017
BACKGROUND: People with severe mental ill health are more likely to smoke than those in the general population. It is therefore important that effective smoking cessation strategies are used to help people with severe mental ill health to stop smoking ...
A Baker, A Baker, AE Evins, AE Evins, AE Evins, AE Evins, AH Weinberger, AL Baker, B O'Brien, BS Wu, C Bullen, C McDonald, E Ratschen, E Weiner, E Weiner, Emily Peckham, Garry Tew, GW Dalack, HK Chen, J Hartmann-Boyce, JM Williams, JM Williams, JM Williams, JW Tidey, KN Chengappa, KR Fontaine, L Banham, Liz Cook, ML Steinberg, ML Steinberg, Q Wu, RC Smith, RM Anthenelli, S Brown, S Fatemi, S Gilbody, Sally Brabyn, SE Adkison, Simon Gilbody, SM Gallagher, TP George, TP George, TP George, VC Wing   +43 more
core   +1 more source